References
- Kropp H, Gerckens L, Sundelof J G, Kahan F M. Antibacterial activity of imipenem: The first thienamycin antibiotic. Rev Infect Dis 1985; 7: S389–S410, Suppl 3
- Neu H, Labthavikul P. Comparative in vitro activity of N-formimidoyi thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob Agents Chemother 1982; 21: 180–187
- Kahan F M, Kropp H, Sundelof J G, Birnbaum J. Thienamycin: Development of imipenem-cilastatin. J Antimicrob Chemother 1983; 12: 1–35, Suppl D
- Scandinavian Study Group. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Lancet 1984; 1: 868–871
- Solomkin J S, Fant W K, Rivera J O, Alexander J W. Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985; 78: 77–83, Suppl 6 A
- Baumgartner J D, Glauser M P. Comparative study of imipenem in severe infections. J Antimicrob Chemother 1983; 12: 141–148, Suppl D
- Diaz-Mitoma F, Harding G KM, Louie T J, Thomson M, James M, Ronald A R. Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections. Rev Infect Dis 1985; 7: S452–S457, Suppl 3
- Calandra G B, Ricci F M, Wang C, Brown K R. Safety and tolerance comparison of imipenem-cilastatin to cephalotin and cefazolin. J Antimicrob Chemother 1983; 12: 125–131, Suppl D
- Calandra G B, Hesney M, Grad C. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam. Eur J Clin Microbiol 1984; 3: 478–487